UPDATE Monday, Feb. 14, 2022, 1:30 p.m. EST—The U.S. Health Resources and Services Administration (HRSA) said, “We are reviewing GSK’s policy and will evaluate next steps as needed.”
Drug manufacturer GlaxoSmithKline (GSK) told 340B covered entities this morning that effective April 1, it will let 340B hospitals without an in-house pharmacy designate just one contract pharmacy for 340B bill to / ship to replenishment orders of nine of its inhaled drugs for asthma, bronchitis, and other breathing problems. If hospitals agree to share their 340B contract pharmacy claims data for the products with GSK they can continue to use multiple contract pharmacies to dispense the drugs.
Drug manufacturer GlaxoSmithKline (GSK) told 340B covered entities this morning that effective April 1, it will let 340B hospitals without an in-house pharmacy designate just one contract pharmacy for 340B bill to / ship to replenishment orders of nine of its inhaled drugs for asthma, bronchitis, and other breathing problems.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
